VECALMYS 6 mg/0.4 mg, modified-release tablet 30 tablets
Active ingredients: Tamsulosin hydrochloride, Solifenacin, Solifenacin succinate, Tamsulosin
Commercialized according to BDPMDispensing in France: Prescription only
Modified-release tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- VECALMYS 6 mg/0,4 mg, comprimé à libération modifiée
- Pharmaceutical form
- comprimé à libération modifiée
- Route of administration
- orale
- Presentation description
- plaquette(s) polyamide aluminium PVC-Aluminium de 30 comprimé(s)
- Marketing authorisation holder
- BESINS HEALTHCARE FRANCE
- Reimbursement according to BDPM
- 30 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 1 Jan 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67179877CIP73025909CIP133400930259092Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| SUCCINATE DE SOLIFÉNACINEcomprimé | 6 mg · un comprimé | SA |
| TAMSULOSINEcomprimé | 0,37 mg · un comprimé | FT |
| CHLORHYDRATE DE TAMSULOSINEcomprimé | 0,4 mg · un comprimé | SA |
| SOLIFÉNACINEcomprimé | 4,5 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.